XIII Annual INFOTEHNA Pharmaceutical Conference

25 - 27 May 2011, Wörthersee/Klagenfurt, Austria.
INFOTEHNA Group, leading provider of Software Solutions for Pharmaceutical Industry, is organizing its traditional (XIII) Annual Pharmaceutical Conference. Event will take place at idyllic alpine lake Woerthersee in southern Austria.

INFOTEHNA's consultants with guest speakers from Agencies and successful pharmaceutical companies will focus on areas of Regulatory Affairs, Research & Development, Quality Assurance and Quality Control.

Pre-conference day - May 25
Pre-conference day will be devided in two workshops: to newcomers INFOTEHNA's software solutions for faster, easier and efficient work with documentation will be presented, along with several case studies. To loyal customers, INFOTEHNA will unveil new functions of our system, some tricks of Submission Management and show demonstration of Training Management Tool. Event organisers will discuss Pharmacovigilance Documentation in electronic system, connection with Regulatory Authorities and much more.

Conference day - May 26
Speakers from successful Pharma companies and Regulatory Agencies will share their experiences and knowledge in 2 Streams:

1) Regulatory Affairs and Pharmacovigilance
2) Quality and Development

In Hands-on corner you will be able to work with INFOTEHNA's system and test its functionalities, consult experts and get answers to any questions concerning the use of INFOTEHNA's solutions.

For further information and registration, please visit:
http://www.infotehna.com/event/373

About INFOTEHNA
INFOTEHNA Group is with more than 20 years in the industry well established provider of hi-end Enterprise Content Management Software, delivering totally integrated solutions for mission-critical business processes in pharmaceutical industry. They are ready to validate and deploy without expensive customization, and designed with compliance regulations and best practices in mind.

INFOTEHNA Expert Series solutions have over 5000 users in more than 20 countries. With offices in Germany, USA, India, Turkey, Slovenia and Croatia, INFOTEHNA is globally present and highly experienced partner of world's largest Life Science companies.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...